ECSP14004595A - 2-tiopirimidinonas - Google Patents
2-tiopirimidinonasInfo
- Publication number
- ECSP14004595A ECSP14004595A ECIEPI20144595A ECPI201404595A ECSP14004595A EC SP14004595 A ECSP14004595 A EC SP14004595A EC IEPI20144595 A ECIEPI20144595 A EC IEPI20144595A EC PI201404595 A ECPI201404595 A EC PI201404595A EC SP14004595 A ECSP14004595 A EC SP14004595A
- Authority
- EC
- Ecuador
- Prior art keywords
- inhibitors
- thiopyrimidinones
- compounds
- treatment
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Photoreceptors In Electrophotography (AREA)
- Cephalosporin Compounds (AREA)
Abstract
La presente invención se refiere a compuestos que son inhibidores de mieloperoxidasa, a composiciones farmacéuticas que contienen estos inhibidores y al uso de estos inhibidores para el tratamiento, por ejemplo, de afecciones cardiovasculares, que incluyen el síndrome coronario agudo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161558605P | 2011-11-11 | 2011-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP14004595A true ECSP14004595A (es) | 2015-11-30 |
Family
ID=47356235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECIEPI20144595A ECSP14004595A (es) | 2011-11-11 | 2014-06-11 | 2-tiopirimidinonas |
Country Status (34)
Country | Link |
---|---|
US (4) | US8835449B2 (es) |
EP (1) | EP2776405A1 (es) |
JP (1) | JP5731718B2 (es) |
KR (1) | KR101650262B1 (es) |
CN (1) | CN103917529B (es) |
AP (1) | AP2014007621A0 (es) |
AR (1) | AR088805A1 (es) |
AU (1) | AU2012335220B2 (es) |
BR (1) | BR112014011254A2 (es) |
CA (1) | CA2853024C (es) |
CL (1) | CL2014000996A1 (es) |
CO (1) | CO6960543A2 (es) |
CR (1) | CR20140179A (es) |
CU (1) | CU20140049A7 (es) |
DO (1) | DOP2014000098A (es) |
EA (1) | EA027324B1 (es) |
EC (1) | ECSP14004595A (es) |
GE (1) | GEP201706656B (es) |
GT (1) | GT201400090A (es) |
HK (1) | HK1196603A1 (es) |
IL (2) | IL232425A (es) |
MA (1) | MA35638B1 (es) |
MD (1) | MD20140044A2 (es) |
MX (1) | MX351299B (es) |
NI (1) | NI201400042A (es) |
PE (1) | PE20161219A1 (es) |
PH (1) | PH12014501032A1 (es) |
SG (1) | SG11201401531RA (es) |
TN (1) | TN2014000195A1 (es) |
TW (2) | TWI526433B (es) |
UA (1) | UA108713C2 (es) |
UY (1) | UY34442A (es) |
WO (1) | WO2013068875A1 (es) |
ZA (1) | ZA201403589B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
EA027324B1 (ru) | 2011-11-11 | 2017-07-31 | Пфайзер Инк. | 2-тиопиримидиноны |
JP6307091B2 (ja) | 2012-12-18 | 2018-04-04 | アルミラル・ソシエダッド・アノニマAlmirall, S.A. | β2アドレナリンアゴニスト活性およびM3ムスカリンアンタゴニスト活性を有する新規のシクロヘキシルおよびキヌクリジニルカルバメート誘導体 |
TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有maba化合物和皮質類固醇之組合 |
TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽 |
TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物 |
US9616063B2 (en) | 2014-12-01 | 2017-04-11 | Astrazeneca Ab | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase |
CN107531647A (zh) * | 2015-05-05 | 2018-01-02 | 辉瑞大药厂 | 2‑硫代嘧啶酮类 |
BR112020008762A2 (pt) | 2017-11-02 | 2020-10-20 | Aicuris Gmbh & Co. Kg | indol-2-carboxamidas amino-tiazol substituídas altamente ativas inovadoras ativas contra o vírus da hepatite b (hbv) |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
WO2024038131A1 (en) | 2022-08-18 | 2024-02-22 | Astrazeneca Ab | Inhibitors of myeloperoxidase |
Family Cites Families (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4088751A (en) | 1972-04-07 | 1978-05-09 | Colgate-Palmolive Company | Self-heating cosmetic |
US4171429A (en) | 1977-03-29 | 1979-10-16 | Research Corporation | Pyrimidine to pyrimidine transformation process |
EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
JPS5770693A (en) | 1980-10-22 | 1982-05-01 | Fuji Photo Film Co Ltd | Desensitizing composition |
EP0422011A1 (de) | 1988-05-05 | 1991-04-17 | BASF Aktiengesellschaft | Mittel auf der basis von uracil-derivaten zur wachstumsförderung und fettreduktion bei tieren |
KR0155168B1 (ko) | 1989-09-29 | 1998-11-16 | 미우라 아끼라 | 6-치환된 아시클로피리미딘 뉴클레오시드 유도체 및 이를 활성성분으로 함유하는 항비루스제 |
JPH0699170B2 (ja) | 1990-01-19 | 1994-12-07 | 日東紡績株式会社 | 耐火被覆材 |
JPH0525144A (ja) | 1991-04-15 | 1993-02-02 | Nissan Chem Ind Ltd | ウラシル誘導体及び有害生物防除剤 |
JPH0525142A (ja) | 1991-07-12 | 1993-02-02 | Nissan Chem Ind Ltd | ウラシル誘導体及び有害生物防除剤 |
JPH0543555A (ja) | 1991-08-13 | 1993-02-23 | Nissan Chem Ind Ltd | ウラシル誘導体及び有害生物防除剤 |
TW284688B (es) | 1991-11-20 | 1996-09-01 | Takeda Pharm Industry Co Ltd | |
GB2263639A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
JPH063761A (ja) | 1992-06-19 | 1994-01-14 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
US6444656B1 (en) | 1992-12-23 | 2002-09-03 | Biochem Pharma, Inc. | Antiviral phosphonate nucleotides |
KR0151811B1 (ko) | 1993-12-21 | 1998-10-15 | 강박광 | 신규한 항바이러스성 2,4-피리미딘디온 유도체 및 그의 제조방법 |
JP3781200B2 (ja) | 1994-04-27 | 2006-05-31 | コニカミノルタホールディングス株式会社 | ハロゲン化銀写真感光材料の処理方法 |
JP3261641B2 (ja) | 1994-04-28 | 2002-03-04 | コニカ株式会社 | ハロゲン化銀写真感光材料の処理方法 |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
SK60097A3 (en) | 1994-11-16 | 1998-01-14 | Synaptic Pharma Corp | Dihydropyrimidines, pharmaceutical composition containing same and use thereof |
US6268369B1 (en) | 1994-11-16 | 2001-07-31 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
US6228861B1 (en) | 1995-11-16 | 2001-05-08 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
WO1997017969A1 (en) | 1995-11-16 | 1997-05-22 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US5719190A (en) | 1996-02-28 | 1998-02-17 | Pfizer Inc. | Inhibition of myeloperoxidase activity |
EP1021185A4 (en) | 1996-05-16 | 2005-09-07 | Synaptic Pharma Corp | DIHYDROPYRIMIDINE AND ITS USES. |
US6172066B1 (en) | 1996-05-16 | 2001-01-09 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6245773B1 (en) | 1996-05-16 | 2001-06-12 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
DE19647380A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
WO1998024780A2 (en) | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidinone and pyridinone compounds and their use |
US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
WO1998024782A2 (en) | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidine compounds and their use |
IL127296A (en) | 1996-12-31 | 2003-01-12 | Reddy Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
DE19731784A1 (de) | 1997-07-24 | 1999-02-04 | Bayer Ag | Substituierte N-Aryl-N-thioxocarbonyl-sulfonamide |
US6211370B1 (en) | 1998-01-13 | 2001-04-03 | Harvard University | Asymmetric cycloaddition reactions |
US6130340A (en) | 1998-01-13 | 2000-10-10 | President And Fellows Of Harvard College | Asymmetric cycloaddition reactions |
AU4084599A (en) | 1998-05-18 | 1999-12-06 | Oklahoma Medical Research Foundation | Resveratrol inhibition of myeloperoxidase |
IL140622A0 (en) | 1998-07-06 | 2002-02-10 | Bristol Myers Squibb Co | Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof |
CA2252144A1 (en) | 1998-10-16 | 2000-04-16 | University Of Alberta | Dual action anticancer prodrugs |
DE19918725A1 (de) | 1999-04-24 | 2000-10-26 | Bayer Ag | Substituierte N-Cyano-sulfonsäureanilide |
DK1175408T3 (da) * | 1999-05-01 | 2005-04-11 | Smithkline Beecham Plc | Pyrimidinonforbindelser |
EA004645B1 (ru) | 1999-06-02 | 2004-06-24 | Янссен Фармацевтика Н.В. | Аминоалкилзамещенные производные бензопирана |
IT1307786B1 (it) * | 1999-07-22 | 2001-11-19 | Bracco Spa | Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali. |
FR2796945B1 (fr) * | 1999-07-30 | 2002-06-28 | Sod Conseils Rech Applic | Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments |
JP2001131133A (ja) | 1999-08-23 | 2001-05-15 | Sankyo Co Ltd | 新規ミエロペルオキシダーゼ阻害物質およびその製造方法 |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
GB2362101A (en) | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
GB0013655D0 (en) | 2000-06-05 | 2000-07-26 | Prolifix Ltd | Therapeutic compounds |
JO2352B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Compounds for the treatment of non-adaptation of the bottom of the uterus |
US6720324B2 (en) | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
EP1299362A4 (en) | 2000-07-05 | 2004-11-03 | Synaptic Pharma Corp | SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE |
AU2001283900A1 (en) | 2000-07-14 | 2002-01-30 | Akzo Nobel N.V. | Stabiliser system comprising hydroxyacids |
DE10034803A1 (de) | 2000-07-18 | 2002-01-31 | Bayer Ag | Substituierte Sulfonsäureanilide |
DE10034800A1 (de) | 2000-07-18 | 2002-01-31 | Bayer Ag | Substituierte Benzostickstoffheterocyclen |
KR100799789B1 (ko) | 2000-07-31 | 2008-01-31 | 브랜데이스 유니버시티 | 키랄 2- 및 3-치환된 카르복실산의 속도론적 분할 |
US6562967B2 (en) | 2000-07-31 | 2003-05-13 | Brandeis University | Kinetic resolutions of chiral 2-and-3-substituted carboxylic acids |
WO2003011799A1 (en) | 2000-07-31 | 2003-02-13 | Brandeis University | Kinetic resolutions of chirat 3- and 3-substituted carboxylic acids |
WO2002033128A2 (en) | 2000-10-18 | 2002-04-25 | Pharmasset Limited | Multiplex quantification of nucleic acids in diseased cells |
KR20090089922A (ko) | 2000-10-18 | 2009-08-24 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
DE10108995A1 (de) | 2001-02-23 | 2002-09-05 | Abbott Gmbh & Co Kg | Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren |
WO2002069903A2 (en) | 2001-03-06 | 2002-09-12 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
ATE346951T1 (de) | 2001-05-08 | 2006-12-15 | Astrazeneca Ab | Test zum nachweis von inhibitoren des enzyms myeloperokidase |
CN101513402B (zh) | 2001-08-10 | 2012-03-21 | 盐野义制药株式会社 | 抗病毒药 |
EP1438292A1 (en) | 2001-10-03 | 2004-07-21 | Pharmacia Corporation | 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
EP1448534A1 (en) | 2001-10-03 | 2004-08-25 | Pharmacia Corporation | 6-membered unsaturated heterocyclic compounds useful for selective inhibition ofthe coagulation cascade |
JP2005525413A (ja) | 2001-10-03 | 2005-08-25 | ファルマシア・コーポレーション | 凝固カスケードの選択的抑制に有用な置換5員多環状化合物 |
CA2462601A1 (en) | 2001-10-03 | 2003-04-10 | Pharmacia Corporation | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
WO2003057677A1 (en) | 2002-01-11 | 2003-07-17 | Syddansk Universitet | Anti-retroviral 5,6-disubstituted acyclopyrimidine nucleoside derivatives |
EA200400980A1 (ru) | 2002-02-27 | 2005-02-24 | Пфайзер Продактс Инк. | Ингибиторы асс |
AU2003216585A1 (en) | 2002-04-10 | 2003-10-20 | Orchid Chemicals And Pharmaceuticals Limited | Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases |
AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
KR101019778B1 (ko) | 2002-05-16 | 2011-03-04 | 바이엘 크롭사이언스 게엠베하 | 피리딘 카복사마이드 유도체 및 이것의 살충제로서의 용도 |
EP1394242A3 (en) | 2002-08-07 | 2004-04-21 | Rohm And Haas Company | Cyclic thioureas and their use as additives for lubricating oils |
EP1394241A1 (en) | 2002-08-07 | 2004-03-03 | Rohm And Haas Company | Cyclic thioureas as additives for lubricating oils |
WO2004037159A2 (en) | 2002-10-23 | 2004-05-06 | Obetherapy Biotechnology | Compounds, compositions and methods for modulating fat metabolism |
AU2004212786A1 (en) | 2003-02-21 | 2004-09-02 | Tripep Ab | Glycinamide derivative for inhibiting HIV replication |
US20050096319A1 (en) | 2003-02-21 | 2005-05-05 | Balzarini Jan M.R. | Identification of compounds that inhibit replication of human immunodeficiency virus |
EP1611120A4 (en) | 2003-04-07 | 2008-04-23 | Cortical Pty Ltd | NEW M THODES FOR THE TREATMENT OF INFLAMMATORY DISEASES |
SE0301232D0 (sv) * | 2003-04-25 | 2003-04-25 | Astrazeneca Ab | Novel use |
US7485604B2 (en) | 2003-05-27 | 2009-02-03 | Fujifilm Corporation | Lubricant composition and method for using and preparing thereof |
US7572581B2 (en) | 2003-06-30 | 2009-08-11 | Roche Molecular Systems, Inc. | 2′-terminator nucleotide-related methods and systems |
US7947817B2 (en) | 2003-06-30 | 2011-05-24 | Roche Molecular Systems, Inc. | Synthesis and compositions of 2'-terminator nucleotides |
CN1906196A (zh) | 2003-12-22 | 2007-01-31 | 吉里德科学公司 | 具有hiv和hcv抗病毒活性的4'-取代的卡波韦-和阿巴卡韦-衍生物以及相关化合物 |
EA013427B1 (ru) | 2004-03-15 | 2010-04-30 | Такеда Фармасьютикал Компани Лимитед | Ингибиторы дипептидилпептидазы |
AU2005247684B2 (en) | 2004-05-12 | 2008-10-23 | Pfizer Products Inc. | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors |
US7745125B2 (en) | 2004-06-28 | 2010-06-29 | Roche Molecular Systems, Inc. | 2′-terminator related pyrophosphorolysis activated polymerization |
US7928207B2 (en) | 2004-06-28 | 2011-04-19 | Roche Molecular Systems, Inc | Synthesis and compositions of nucleic acids comprising 2′-terminator nucleotides |
EP1616874A1 (en) | 2004-07-14 | 2006-01-18 | Universiteit Gent | Mono- and bicyclic compounds with therapeutic activity and pharmaceutical compositions including them |
EP1778778A4 (en) | 2004-08-12 | 2011-04-27 | King Industries Inc | METAL-ORGANIC COMPOSITIONS AND COATING COMPOSITIONS |
US7485729B2 (en) | 2004-08-12 | 2009-02-03 | King Industries, Inc. | Organometallic compositions and coating compositions |
US20060100226A1 (en) | 2004-09-10 | 2006-05-11 | Sikorski James A | 2-Thiopyrimidinones as therapeutic agents |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
WO2006070292A2 (en) | 2004-10-12 | 2006-07-06 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
SE0402591D0 (sv) | 2004-10-25 | 2004-10-25 | Astrazeneca Ab | Novel use |
MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
US20060194821A1 (en) | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
EP1731911A1 (fr) | 2005-06-07 | 2006-12-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Procédé utile pour la détection d'encéphalopathies |
US7399786B2 (en) | 2005-06-30 | 2008-07-15 | Bexel Pharmaceuticals, Inc. | Derivatives of amino acids for treatment of obesity and related disorders |
EP1920072A2 (en) | 2005-07-01 | 2008-05-14 | Dako Denmark A/S | In situ hybridization detection method |
EP1920073A2 (en) | 2005-07-01 | 2008-05-14 | Dako Denmark A/S | Method of simultaneously visualizing multiple biological targets |
CN101282962A (zh) | 2005-08-12 | 2008-10-08 | 先灵公司 | 用于治疗炎性疾病的化合物 |
EP1963329B1 (en) | 2005-11-30 | 2013-01-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
RU2438671C2 (ru) | 2005-12-28 | 2012-01-10 | Такеда Фармасьютикал Компани Лимитед | Терапевтическое средство против диабета |
DE102006000651A1 (de) | 2006-01-03 | 2007-07-12 | Degussa Gmbh | Präparation aus Ionischen Flüssigkeiten und Harzen |
DE102006000649A1 (de) | 2006-01-03 | 2007-07-05 | Degussa Gmbh | Universell einsetzbare Zusammensetzungen |
JP5025142B2 (ja) | 2006-02-27 | 2012-09-12 | 株式会社東芝 | モータ制御装置 |
JP5025144B2 (ja) | 2006-02-28 | 2012-09-12 | Jx日鉱日石エネルギー株式会社 | 内燃機関用潤滑油組成物 |
TW200806667A (en) | 2006-04-13 | 2008-02-01 | Astrazeneca Ab | New compounds |
SI2463283T1 (sl) | 2006-04-20 | 2014-09-30 | Pfizer Products Inc. | Kondezirane fenil amino heterociklične spojine za preprečevanje in zdravljenje bolezni, ki jih posreduje glukokinaza |
TW200808649A (en) | 2006-05-31 | 2008-02-16 | Du Pont | Process for purifying perfluorinated products |
TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
JP2009539829A (ja) * | 2006-06-05 | 2009-11-19 | アストラゼネカ・アクチエボラーグ | ミエロペルオキシダーゼ阻害剤としてのピロロ[3,2−d]ピリミジン−4−オン誘導体 |
DK2048145T3 (da) | 2006-08-04 | 2011-04-04 | Toyama Chemical Co Ltd | Forstærker af aktiviteten af proteinkinase C indeholdende alkyletherderivat eller et salt deraf |
WO2008023249A1 (en) | 2006-08-24 | 2008-02-28 | Chemfit Speciality Chemicals (Pty) Ltd | Polyvinylchloride composition |
JP2010510245A (ja) | 2006-11-21 | 2010-04-02 | スミスクライン ビーチャム コーポレーション | 抗ウイルス化合物 |
MX2009005604A (es) | 2006-11-29 | 2009-06-08 | Pfizer Prod Inc | Inhibidores espiro cetona de acetil-coa carboxilasa. |
US20080153697A1 (en) | 2006-12-22 | 2008-06-26 | E. I. Dupont De Nemours And Company | Mixtures of ammonia and ionic liquids |
US8633186B2 (en) | 2007-06-08 | 2014-01-21 | Senomyx Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
AU2008271114A1 (en) | 2007-06-29 | 2009-01-08 | Korea Research Institute Of Chemical Technology | Novel HIV reverse transcriptase inhibitors |
KR20100041798A (ko) | 2007-06-29 | 2010-04-22 | 한국화학연구원 | 신규 hiv 역전사효소 억제제 |
US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
JP5043555B2 (ja) | 2007-08-08 | 2012-10-10 | 株式会社カネカ | 硬化性組成物 |
US20090053176A1 (en) | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Combination 937 |
US20090054468A1 (en) | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
EP2217588A4 (en) | 2007-11-02 | 2013-12-04 | Methylgene Inc | INHIBITORS OF HISTONE DEACETYLASE |
GB0722680D0 (en) | 2007-11-19 | 2007-12-27 | Topotarget As | Therapeutic compounds and their use |
JP2009167179A (ja) | 2007-12-21 | 2009-07-30 | Daiichi Sankyo Co Ltd | 環状アミン化合物を含有する医薬 |
CN102036956A (zh) | 2008-03-21 | 2011-04-27 | 柯罗瑞恩制药有限公司 | 取代的吡咯烷和哌啶化合物、它们的衍生物、以及用于治疗疼痛的方法 |
US8236446B2 (en) | 2008-03-26 | 2012-08-07 | Ada Technologies, Inc. | High performance batteries with carbon nanomaterials and ionic liquids |
WO2009129120A2 (en) | 2008-04-15 | 2009-10-22 | Rfs Pharma, Llc | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
GB2472554B (en) | 2008-05-05 | 2012-12-05 | Ada Technologies Inc | High performance carbon nanocomposites for ultracapacitors |
ES2545231T3 (es) | 2008-05-28 | 2015-09-09 | Pfizer Inc. | Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa |
CA2724603A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
US20110130365A1 (en) | 2008-07-29 | 2011-06-02 | Benbow John W | Fluorinated Heteroaryls |
KR101446454B1 (ko) | 2008-08-28 | 2014-10-06 | 화이자 인코포레이티드 | 다이옥사-바이사이클로[3.2.1]옥테인-2,3,4-트라이올 유도체 |
GB0818063D0 (en) * | 2008-10-02 | 2008-11-05 | Univ Dundee | Compounds |
JP5206367B2 (ja) | 2008-11-27 | 2013-06-12 | コニカミノルタエムジー株式会社 | ウレア化合物を含む有機圧電材料 |
TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
MY151246A (en) | 2009-03-11 | 2014-04-30 | Pfizer | Benzofuranyl derivatives |
WO2010103438A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
CA2754523A1 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
JP2012524816A (ja) | 2009-04-23 | 2012-10-18 | インバスク・セラピユーテイクス・インコーポレイテツド | 心血管疾患の治療のための組成物及び方法 |
WO2010124237A1 (en) | 2009-04-24 | 2010-10-28 | Novabay Pharmaceuticals Inc. | Methods of treating infections of the nail |
CA2759891A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
JP2012526097A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Gpr119調節因子 |
US20120122948A1 (en) | 2009-05-27 | 2012-05-17 | Universite Libre De Beuxelles | 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors |
WO2010138901A1 (en) | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Carboxylic acid-containing compounds, derivatives thereof, and related methods of use |
GEP20135907B (en) | 2009-06-05 | 2013-08-12 | Pfizer | L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators |
LT2445502T (lt) | 2009-06-25 | 2017-09-25 | Alkermes Pharma Ireland Limited | Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui |
JP5732453B2 (ja) | 2009-06-25 | 2015-06-10 | アルカーメス ファーマ アイルランド リミテッド | Nh酸性化合物のプロドラッグ |
US9790252B2 (en) | 2009-07-01 | 2017-10-17 | Cornell University | 2-fluorinated riboses and arabinoses and methods of use and synthesis |
WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
DE102009037300A1 (de) | 2009-08-14 | 2011-02-17 | Merck Patent Gmbh | Tetracyanoborate als Schmierstoffe |
WO2011045415A2 (en) | 2009-10-15 | 2011-04-21 | Guerbet | New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
WO2011057220A2 (en) | 2009-11-09 | 2011-05-12 | Northwestern University | Compositions and methods for treating lymphoma |
FR2953145B1 (fr) | 2009-11-30 | 2013-07-19 | Inst Francais Du Petrole | Solution absorbante contenant un inhibiteur de degradation derive de la pyrimidine ou de la triazine et procede d'absorption de composes acides contenus dans un effluent gazeux |
WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
US20130085133A1 (en) | 2010-02-08 | 2013-04-04 | Sourthern Research Institute Office of Commercialization and Intellectual Prop. | Anti-viral treatment and assay to screenfor anti-viral agent |
CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
CA2802733C (en) | 2010-06-24 | 2017-11-21 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
ES2352926B1 (es) | 2010-12-07 | 2012-01-12 | Universidad De Granada | Fenucil deuterado y derivados, procedimiento para su preparación y usos de los mismos. |
EA027324B1 (ru) * | 2011-11-11 | 2017-07-31 | Пфайзер Инк. | 2-тиопиримидиноны |
JP6003761B2 (ja) | 2013-03-27 | 2016-10-05 | 富士ゼロックス株式会社 | 送風管、送風装置及び画像形成装置 |
CN107531647A (zh) * | 2015-05-05 | 2018-01-02 | 辉瑞大药厂 | 2‑硫代嘧啶酮类 |
-
2012
- 2012-10-28 EA EA201490688A patent/EA027324B1/ru not_active IP Right Cessation
- 2012-10-28 MD MDA20140044A patent/MD20140044A2/ro not_active Application Discontinuation
- 2012-10-28 EP EP12799609.8A patent/EP2776405A1/en not_active Withdrawn
- 2012-10-28 MX MX2014005721A patent/MX351299B/es active IP Right Grant
- 2012-10-28 AU AU2012335220A patent/AU2012335220B2/en not_active Ceased
- 2012-10-28 GE GEAP201213463A patent/GEP201706656B/en unknown
- 2012-10-28 AP AP2014007621A patent/AP2014007621A0/xx unknown
- 2012-10-28 UA UAA201404418A patent/UA108713C2/uk unknown
- 2012-10-28 KR KR1020147015697A patent/KR101650262B1/ko active IP Right Grant
- 2012-10-28 WO PCT/IB2012/055949 patent/WO2013068875A1/en active Application Filing
- 2012-10-28 SG SG11201401531RA patent/SG11201401531RA/en unknown
- 2012-10-28 JP JP2014540581A patent/JP5731718B2/ja not_active Expired - Fee Related
- 2012-10-28 BR BR112014011254A patent/BR112014011254A2/pt not_active Application Discontinuation
- 2012-10-28 CA CA2853024A patent/CA2853024C/en not_active Expired - Fee Related
- 2012-10-28 PE PE2014001103A patent/PE20161219A1/es not_active Application Discontinuation
- 2012-10-28 CN CN201280055082.9A patent/CN103917529B/zh not_active Expired - Fee Related
- 2012-11-07 TW TW104103035A patent/TWI526433B/zh not_active IP Right Cessation
- 2012-11-07 US US13/670,852 patent/US8835449B2/en not_active Expired - Fee Related
- 2012-11-07 TW TW101141370A patent/TWI480269B/zh not_active IP Right Cessation
- 2012-11-08 AR ARP120104212A patent/AR088805A1/es unknown
- 2012-11-09 UY UY0001034442A patent/UY34442A/es not_active Application Discontinuation
-
2013
- 2013-05-02 US US13/875,604 patent/US8841314B2/en active Active
-
2014
- 2014-04-17 CL CL2014000996A patent/CL2014000996A1/es unknown
- 2014-04-22 CR CR20140179A patent/CR20140179A/es unknown
- 2014-04-28 CU CUP2014000049A patent/CU20140049A7/es unknown
- 2014-05-01 IL IL232425A patent/IL232425A/en active IP Right Grant
- 2014-05-02 TN TNP2014000195A patent/TN2014000195A1/fr unknown
- 2014-05-06 PH PH12014501032A patent/PH12014501032A1/en unknown
- 2014-05-09 DO DO2014000098A patent/DOP2014000098A/es unknown
- 2014-05-09 GT GT201400090A patent/GT201400090A/es unknown
- 2014-05-09 NI NI201400042A patent/NI201400042A/es unknown
- 2014-05-09 CO CO14100184A patent/CO6960543A2/es unknown
- 2014-05-12 MA MA37018A patent/MA35638B1/fr unknown
- 2014-05-16 ZA ZA2014/03589A patent/ZA201403589B/en unknown
- 2014-06-09 US US14/299,497 patent/US9399626B2/en not_active Expired - Fee Related
- 2014-06-11 EC ECIEPI20144595A patent/ECSP14004595A/es unknown
- 2014-10-07 HK HK14109952.1A patent/HK1196603A1/zh not_active IP Right Cessation
-
2016
- 2016-06-24 US US15/191,943 patent/US9873673B2/en not_active Expired - Fee Related
- 2016-11-17 IL IL249039A patent/IL249039B/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP14004595A (es) | 2-tiopirimidinonas | |
ECSP11011390A (es) | Compuestos espiro-amidas sustituidas | |
GT201200230A (es) | Inhibidores del virus de la hepatitis c | |
CY1119245T1 (el) | Φαρμακευτικη συνθεση καρβετοκινης | |
ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
ECSP13012519A (es) | Compuestos sustituidos de benzamida | |
CL2015000944A1 (es) | Compuestos de benceno sustituido | |
CR20110467A (es) | Derivados de benzofuranilo como inhibidores de la glucoquinasa | |
CR20150326A (es) | Inhibidores de autotaxina | |
CR20140229A (es) | Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona | |
DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
BR112014030473A2 (pt) | novo diazaespirocicloalcano e azaespirocicloalcano | |
BR112016014020A8 (pt) | moduladores de tetra-hidropiridopirazinas de gpr6. | |
UY33735A (es) | Compuestos antivirales | |
CR20140161A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
ECSP14013325A (es) | Piridopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr) | |
CR20140361A (es) | Inhibidores de pde9 con estructura básica de imidazotriazinona | |
CR20140071A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
BR112012019529A2 (pt) | inibidores de d-nitrosoglutationa redutase | |
BR112014015905A2 (pt) | composição | |
CU24263B1 (es) | Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer | |
BR112012023836A2 (pt) | composto tricíclicos e inibidores de pbk contendo os mesmos | |
GT201500247A (es) | Imidazopiridazinas sustituidas | |
CO6321288A2 (es) | Sales de compuestos inhibidores de vih | |
CL2014001862A1 (es) | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. |